Recommended Dosage of Ciprofloxacin (Ciplox)
The standard adult dosage for ciprofloxacin (Ciplox) is 500-750 mg orally twice daily, with specific dosing dependent on the type and severity of infection. 1
Adult Dosing Guidelines
- For most common infections, 500 mg twice daily is the standard dose 1
- For severe or complicated infections, 750 mg twice daily is recommended 1
- Treatment duration typically ranges from 7-14 days for most infections, though some conditions require longer treatment 1
Specific Infection Types (Adult Dosing)
- Lower respiratory tract infections: 500 mg twice daily (mild/moderate) or 750 mg twice daily (severe) 1
- Urinary tract infections: 250-500 mg twice daily 1
- Skin and skin structure infections: 500 mg twice daily (mild/moderate) or 750 mg twice daily (severe) 1
- Bone and joint infections: 500-750 mg twice daily for at least 4-6 weeks 1
- Intra-abdominal infections: 500 mg twice daily for 7-14 days 1
Pediatric Dosing Guidelines
- For children: 10-15 mg/kg every 12 hours, not to exceed 1 g per day 2
- For neonates: 15 mg/kg twice daily 2
- Maximum pediatric dose: 750 mg per dose 1
Dosing in Special Populations
Renal Impairment
- Normal renal function: Standard dosing 1
- Creatinine clearance 30-50 mL/min: 250-500 mg every 12 hours 1
- Creatinine clearance 5-29 mL/min: 250-500 mg every 18 hours 1
- Hemodialysis or peritoneal dialysis: 250-500 mg every 24 hours (after dialysis) 1
Route of Administration Conversion
- 500 mg oral tablet twice daily is equivalent to 400 mg IV twice daily 1
- 750 mg oral tablet twice daily is equivalent to 400 mg IV every 8 hours 1
Clinical Considerations
- Oral ciprofloxacin is rapidly and well absorbed with no substantial loss by first-pass metabolism 2
- Maximum serum concentrations are attained 1-2 hours after oral dosing 2
- For severe infections with poor clinical response, therapeutic drug monitoring may be considered 2
- Target serum levels for 500 mg twice daily: trough level 1 mg/L, peak level 3 mg/L 2
- Target serum levels for 750 mg twice daily: trough level 1.5 mg/L, peak level 4.5 mg/L 2
Monitoring Recommendations
- ECG monitoring: baseline, 2 weeks, and after addition of any new medication known to prolong QT interval 2
- Blood glucose monitoring in diabetic patients due to risk of hypoglycemia 2
- Routine toxicity monitoring (FBC, U&Es, LFTs) should be performed intermittently throughout treatment 2
Common Adverse Effects
- Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, dyspepsia 2
- Dermatological: rash 2
- Administration site reactions (with IV formulation) 2